Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma

T cells are expanded and express GZMK/B. Our data suggest nivolumab drives both maintenance and replacement of previously expanded T cell clones, but only maintenance correlates with response. We hypothesize that maintenance and boosting of a pre-existing response is a key element of anti-PD-1 mode of action.

Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma | Litlas